Pharma Outsourcing (CRO)
All research in Pharma Outsourcing (CRO) — 3 reports.
Fortrea is a global CRO spun out of Labcorp in 2023, focused on Phase II-IV clinical operations and clinical pharmacology, with 2025 revenue of $2.723 billion. Its book-to-bill has stayed above 1.1x for three consecutive quarters, but the midpoint of 2026 revenue guidance still implies a decline and gross debt is about 5.6x adjusted EBITDA. Research rating Watch: early order recovery is visible, while revenue decline and high leverage have not yet been resolved.
ICON plc (ICLR) is one of the world's leading clinical research outsourcing providers, or CROs. The 2026 accounting restatement confirmed control failures and a one-time $3.9 billion backlog reduction, yet 2025 free cash flow still reached $862 million, putting the company into a valuation reset under a governance discount. Report rating Hold: the valuation already reflects part of the bad news, but governance repair is not yet strong enough to support a Buy rating, with an ideal buy zone of $108 to $116.
Medpace Holdings is one of the leading U.S. full-service clinical CROs, focused on small and mid-sized biotech clients, founder-controlled, debt-free, and an exceptional high-ROIC compounder. The core thesis is that business quality remains outstanding, but current valuation, weakening leading indicators, and biotech funding-cycle exposure leave little margin of safety. Research rating Watch: a high-quality compounder worth monitoring, with a better entry point likely below $380 or after book-to-bill recovers above 1.0x.